Skip to main content
TipRanks
Go Ultimate75% OFF

InspireMD (II2) Q3 2026 Earnings Report

0 Followers

DE:II2 Q3 2026 EPS Results

Actual EPS
-EUR 0.11
Consensus EPS
-EUR 0.14
Beat/Miss
Beat by +EUR 0.03
One Year Ago EPS
-EUR 0.15

DE:II2 Q3 2026 Revenue Results

Actual Revenue
EUR 2.03M
Expected Revenue
EUR 1.81M
Beat/Miss
Beat by +EUR 223.16K
YoY Revenue Growth
-11.14%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/12/2026
Time
After Close
Conference Call
Thursday, November 12, 2026
DE:II2 Upcoming Earnings

InspireMD's next earnings date is estimated for March 9, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:II2 Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 12, 2026|% Change Since:-15.83%|
Earnings Call Sentiment|Positive

The call was broadly positive, driven by FDA approval of CGuard Prime for TCAR, strong pivotal-trial results, an expanded U.S. market opportunity, immediate commercial launch readiness, international growth, and progress across the product pipeline. These positives were tempered by an 11% decline in total revenue, minimal U.S. sales following the voluntary recall, substantially lower gross margin, reduced cash and securities, a 20% workforce reduction, and the need for additional financing. Overall, management conveyed confidence in the company's next growth phase while acknowledging meaningful financial and execution work ahead.

Company Guidance

InspireMD expects to immediately pursue an approximately 40,000 annual procedure expansion in its U.S. addressable market, with CGuard Prime product already shipping and cases expected to begin immediately; it currently anticipates an FDA submission for the CGuard Prime 135 CAS delivery system before year's end and reentry of this platform in the first half of 2027, subject to regulatory review and approval; it currently expects a planned release of its proprietary micro puncture kit early Q1 2027; CGUARDIANS III enrollment is active, with timelines discussed for end of 2027 continuing to hold; and it expects incremental savings starting in Q4 and carrying over into the first several quarters of next year, with incremental investments again in sales and marketing in the back half of the year depending on the sales ramp and progress in launching CGuard Prime 80.

  • FDA Approval for CGuard Prime TCAR SystemThe FDA approved the CGuard Prime TransCarotid Stent System for TCAR procedures, which management described as one of the most significant milestones in the company's history and a return to the U.S. market.
  • Strong CGUARDIANS II Clinical ResultsThe CGUARDIANS II pivotal trial supporting approval demonstrated 100% acute device success among 50 patients, with no deaths, strokes, or myocardial infarctions through 30 days, and complete stent patency at 30 days among evaluated patients.
  • Expanded U.S. Addressable MarketThe TCAR indication expands InspireMD's U.S. addressable market by approximately 40,000 annual procedures, effectively doubling the company's opportunity.
  • Commercial Launch ReadinessManagement said the company was ready to launch CGuard Prime, with product already being shipped, the Miami facility operational, account approvals and plans in place, and a commercial team prepared to execute. Management expects cases to begin immediately.
  • Broadening Carotid Product StrategyThe company plans to make CGuard available across both TCAR and transfemoral CAS procedures, pursuing a broader carotid intervention platform serving different patient and physician needs.
  • Extensive Global Clinical ExperienceThe CGuard implant has been used in more than 75,000 procedures globally. Management said the clinical evidence and proprietary MicroNet mesh technology support the device's value in treating lesions and providing durable protection against stroke.
  • International Revenue GrowthThird-quarter international revenue increased approximately 9% year over year to $2.2 million. For the first nine months of 2026, international revenue increased approximately 24% to $6.6 million, reflecting continued adoption of the CGuard platform.
  • International Constant-Currency GrowthInternational revenue growth was 10% on a constant-currency basis, with foreign exchange representing approximately a 1% drag on reported growth.
  • Progress on CGuard CAS Delivery SystemThe company has implemented design enhancements to the CGuard Prime 135 CAS delivery system following the voluntary recall. Validation and performance testing are underway, with an FDA submission anticipated before year-end and planned reentry in the first half of 2027, subject to regulatory review and approval.
  • Original CGuard System Remains Under FDA ReviewThe original CGuard carotid stent system for CAS remains under FDA review. Management continues to anticipate FDA feedback by the end of 2026 and said all requested information has been provided.
  • Progress on SwitchGuard Clinical TrialEnrollment is progressing in the CGUARDIANS III pivotal trial evaluating the proprietary SwitchGuard neuroprotection system for TCAR. Management said more sites are being activated, enrollment momentum is continuing, and the target for approval by the end of 2027 remains unchanged.
  • Planned Micro Puncture KitInspireMD plans to introduce a proprietary micro puncture kit to support vascular access for TCAR procedures, with a planned release expected in early Q1 2027.
  • Strengthened Leadership and OrganizationThe company appointed Kathy Kennedy as Senior Vice President of Global Sales and Marketing and promoted or added key leaders in engineering, clinical, regulatory, and operations functions to support the launch and future approvals.
  • Lower Operating ExpensesThird-quarter operating expenses were $10.2 million, down $3.7 million, or 27%, from $13.9 million in the third quarter of 2025. Management attributed the decrease primarily to the workforce reduction and expects incremental savings beginning in Q4 and continuing through the first several quarters of next year.
  • Narrower Net LossThird-quarter net loss was $9.8 million, or $0.12 per basic and diluted share, compared with a net loss of $12.7 million, or $0.17 per share, in the third quarter of 2025.
  • Potential Financing and Warrant ProceedsThe company announced a proposed underwritten equity public offering intended to support U.S. commercialization and strategic priorities. Separately, holders of the amended Series J and K warrants could generate up to $10 million of net proceeds if exercised in full during the 20-day expiration period.

DE:II2 Earnings History

DE:II2 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 09, 20272026 (Q4)-0.12--0.13――
Nov 12, 20262026 (Q3)-0.14-0.11-0.1529.41% (+0.05)
Aug 17, 20262026 (Q2)-0.18-0.15-0.2434.62% (+0.08)
May 04, 20262026 (Q1)-0.16-0.15-0.227.27% (+0.05)
Mar 18, 20262025 (Q4)-0.18-0.13-0.1726.32% (+0.05)
Nov 04, 20252025 (Q3)-0.18-0.15-0.15-6.25% (-0.01)
Aug 05, 20252025 (Q2)-0.24-0.24-0.2-18.18% (-0.04)
May 09, 20252025 (Q1)-0.18-0.20-0.19-4.76% (-0.01)
Mar 12, 20252024 (Q4)-0.18-0.17-0.15-18.75% (-0.03)
Nov 12, 20242024 (Q3)-0.18-0.15-0.14-6.67% (-0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed